SCHEMBL4178536

SCHEMBL4178536

O=C(c1csc(NS(=O)(=O)c2ccccc2)n1)N1CCCC(Oc2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 3/20 0.42
TRPC6 Q9Y210 3/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
RAB9A P51151 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
SPR P35270 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SCD O00767 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4177020 0.94 TRPC3 (0.51) TRPC3TRPC6ALDH1A1SMN1; SMN2HPGD
SCHEMBL4306708 0.94 TRPC3 (0.44) TRPC3TRPC6ALDH1A1SPRCYP2C9
SCHEMBL4184017 0.90 KAT6A (0.42) TRPC3TRPC6KDM4EGAAMAPT
SCHEMBL4173605 0.86 NPC1 (0.41) TRPC3TRPC6ALDH1A1SMN1; SMN2NPC1
SCHEMBL4181072 0.86 TRPV4 (0.40) TRPC3TRPC6CRHBPCRHR2KAT6A
SCHEMBL4176042 0.85 ALDH1A1 (0.47) TRPC3TRPC6ALDH1A1SMN1; SMN2NPC1
SCHEMBL4165262 0.84 ALDH1A1 (0.41) TRPC3TRPC6ALDH1A1SMN1; SMN2NPC1
SCHEMBL4176347 0.83 ALDH1A1 (0.43) TRPC3TRPC6ALDH1A1NPC1RAB9A
SCHEMBL4176180 0.83 ALDH1A1 (0.43) TRPC3TRPC6ALDH1A1NPC1RAB9A
SCHEMBL4321539 0.83 TRPC3 (0.47) TRPC3TRPC6ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 TRPC3 57/4885TRPC6 84/4885ALDH1A1 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.